Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
复制标题
DOI：
10.1016/j.ejca.2006.03.015
复制
发表时间：
2006-08-01
影响因子：
8.4
通讯作者：
Niroumand, M.
中科院分区：
文献类型：
--
作者：
Duran, I.;Siu, L. L.;Niroumand, M.
本研究的目的是回顾我们的经验，关于哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂替西罗莫司的肺毒性，讨论潜在的致病机制，并提出管理策略。回顾了22例接受每周一次替西罗莫司25 mg治疗的患者的病历和放射学报告。22例患者中有8例（36%）发生了与药物性肺炎相符的肺部异常。半数无症状，在有症状的患者中，呼吸困难和干咳是最常见的。影像学上有两种不同的模式，磨玻璃样阴影和肺实质实变。这种毒性的管理是可变的，从不干预到停药。在我们的经验中，替西罗莫司可能导致药物性肺炎的发生率高于以前的报道。表现及其严重程度是可变的。治疗前肺功能异常或有肺部疾病史的受试者发生这种毒性的风险可能会增加。
The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic and in those with symptoms, dyspnea and dry cough were the most common. Radiologically two different patterns, ground glass opacities and lung parenchymal consolidation, were described. The management of this toxicity was variable, ranging from no intervention to discontinuation of the drug. In our experience temsirolimus may cause drug-induced pneumonitis at a higher incidence than that previously reported. The presentation and its severity are variable. The risk of developing this toxicity may be increased among subjects with abnormal pretreatment pulmonary functions or history of lung disease.